Sareum granted cancer treatment patent
UK-based cancer drug company Sareum has been granted a patent for an invention forming part of its treatment methods.
Sareum said the patent, granted by the European Patent Office, covered compounds linked to its CHK1 (Checkpoint Kinase 1) cancer programme.
CHK1 is used when controlling a cancer cell’s response to DNA damage, which could be a consequence of the cancer itself or intentionally caused by chemotherapy or radiotherapy.
The patent, EP2288601, has already been granted in the US, the Cambridge-based company said.
“This patent is part of a wide IP estate which, if granted in its current form, would provide broad geographical protection for the CHK1 programme,” Sareum said in a statement today, (September 22).
Chief executive, Tim Mitchell added: “The IP that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value”.
The CHK1 cancer programme is a co-development collaboration between the Cancer Research Technology Pioneer Fund, investment company BACIT Ltd and Sareum.
